SARS-CoV-2 Variants in Patients with Immunosuppression
Top Cited Papers
- 5 August 2021
- journal article
- editorial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 385 (6), 562-566
- https://doi.org/10.1056/nejmsb2104756
Abstract
Patients with immunosuppression are at risk for prolonged infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In several case reports, investigators have indicated that multimutational SARS-CoV-2 variants can arise during the course of such persistent cases of coronavirus disease 2019 (Covid-19).1-4 These highly mutated variants are indicative of a form of rapid, multistage evolutionary jumps (saltational evolution; see Glossary), which could preferentially occur in the milieu of partial immune control.2,3 The presence of a large number of mutations is also a hallmark of the variants of concern — including B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), and B.1.617.2 (delta)5 — which suggests that viral evolution in immunocompromised patients may be an important factor in the emergence of such variants. Since a large number of persons globally are living with innate or acquired immunosuppression, the association between immunosuppression and the generation of highly transmissible or more pathogenic SARS-CoV-2 variants requires further delineation and mitigation strategies.Keywords
This publication has 14 references indexed in Scilit:
- Detection of a SARS-CoV-2 variant of concern in South AfricaNature, 2021
- Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7Nature, 2021
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19Science, 2021
- Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care WorkersThe New England Journal of Medicine, 2021
- SARS-CoV-2 evolution during treatment of chronic infectionNature, 2021
- Neutralising antibodies in Spike mediated SARS-CoV-2 adaptationPublished by Cold Spring Harbor Laboratory ,2020
- Persistence and Evolution of SARS-CoV-2 in an Immunocompromised HostThe New England Journal of Medicine, 2020
- Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with CancerCell, 2020
- Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack RateJournal of Clinical Microbiology, 2020
- Enhanced neonatal Fc receptor function improves protection against primate SHIV infectionNature, 2014